Animal Models of Diabetic Complications Consortium

The summary for the Animal Models of Diabetic Complications Consortium grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Animal Models of Diabetic Complications Consortium: This is a Request for Applications (RFA) for Pathobiology Sites to support years 6-10 of the Animal Models of Diabetic Complications Consortium (AMDCC). The AMDCC was established in 2001 to generate and phenotype new models of diabetic complications. Information about the current AMDCC can be found at http://www.amdcc.org/. AMDCC Pathobiology Sites will (1) propose new mouse models to be developed by the Consortium that will faithfully replicate one or more diabetic complications, and (2) discover and characterize the basic pathophysiologic mechanisms underlying disease in these and other models of complications. Pathobiology Sites funded by this RFA will work together as a Consortium with a Mouse Generation and Husbandry Core (MGHC) and Coordinating and Bioinformatics Unit (CBU; http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-05-012.html), with substantial involvement from NIH staff. Applications for the MGHC and CBU will be solicited separately. In response to this RFA the participating Institutes anticipate awarding up to 14 Pathobiology Sites covering all major complications of diabetes. The total amount to be awarded is $5.25 million for each of 5 years. Individual Pathobiology Site awards may not exceed 250K direct costs per year during the project period. This RFA will use the U01 Cooperative Agreement mechanism. The AMDCC will work closely with the Mouse Metabolic Phenotyping Centers (MMPCs). The MMPCs (http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-05-008.html) conduct detailed metabolic phenotyping of genetically altered mice and other mouse models that are useful for understanding diabetes and its complications, obesity, and related metabolic diseases or conditions. Mice generated under the auspices of the AMDCC will be shipped to MMPC facilities to be phenotyped using a standardized battery of tests as directed by the AMDCC Executive Steering Committee (ESC). Phenotyping proposed by the Pathobiology Sites should not overlap with existing MMPC services. Information about the current MMPCs, including a catalog of services, guidelines and policies, can be found at http://www.mmpc.org/. For-profit and non-profit organizations are eligible, including public or private institutions, units of state and local governments, eligible agencies of the federal government, domestic or foreign institutions/organizations. Any individual with the skills, knowledge, and resources necessary to execute the functions proposed for an AMDCC Pathobiology Site is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. Applicants may submit more than one application, provided they are scientifically distinct. See Section IV.1 for application materials. Telecommunications for the hearing impaired is available at TTY 301-451-0088.